A Study of ARRY-520 in Patients With Advanced Cancer

NCT00462358 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: ARRY-520, KSP(Eg5) inhibitor; intravenous
DRUG: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Sponsor

Array Biopharma, now a wholly owned subsidiary of Pfizer